Proton therapy reduces radiation to nontargeted tissues, but for men with localized prostate cancer that may not translate to better outcomes, according to early results from the large prospective ...
Combining oncolytic adenovirus-mediated cytotoxic gene therapy (OAMCGT) with intensity modulated radiation therapy (IMRT) reduces the risk of having a positive prostate biopsy two years after ...
In a randomized trial of men with intermediate-risk prostate cancer, stereotactic body radiotherapy (SBRT) improved bowel-related quality of life vs moderately hypofractionated intensity-modulated ...
The phase 3 NRG GU-005 trial did not show a DFS benefit for SBRT vs IMRT in intermediate-risk prostate cancer, but SBRT decreased rectal toxicity. Stereotactic body radiation therapy (SBRT) preserves ...
SBRT is not superior to IMRT for DFS at 3 years, but it is safe and might permit better bowel quality of life. In men with favorable intermediate-risk prostate cancer, modest-dose stereotactic body ...
For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced patient-reported side effects compared to longer courses of radiation, according to ...
Risk of Bleomycin-Related Pulmonary Toxicities and Operative Morbidity After Postchemotherapy Retroperitoneal Lymph Node Dissection in Patients With Good-Risk Germ Cell Tumors Men were randomly ...
Please provide your email address to receive an email when new articles are posted on . Men assigned SBRT reported fewer adverse effects, but longer radiation courses may offer better biochemical ...
UCLA investigators present the latest radiotherapy research at the American Society for Radiation Oncology annual meeting ...
As ProCure Proton Therapy Center continues health education efforts during National Prostate Cancer Awareness Month, the provider is highlighting a patient story with a distinctive vantage point.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results